Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatio
Not Applicable
- Conditions
- Subfoveal type 2 choroidal neovascularization
- Registration Number
- JPRN-UMIN000016870
- Lead Sponsor
- agoya City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
eyes with previous photodynamic therapy, medication for glaucoma, diabetic retinopathy, epiretinal membrane, vitreomacular traction, or high myopia (-6.0 diopters or worse)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best-ocrrected visual acuity
- Secondary Outcome Measures
Name Time Method central retinal thickness and macular volume on optical coherence tomography